Visit our Booth #104 to meet team members and learn more about the impact Moffitt is making in cancer research, outcomes and advancements.
Follow Moffitt to learn more about Moffitt’s research and breakthroughs:
LinkedIn
X | MoffittNews
Email
Moffitt Cancer Center is proud to join leading experts from around the globe at the 2025 Society of Hematology Oncology (SOHO) Annual Meeting this September 3-6. Our faculty will present the latest advances in the diagnosis, treatment, and research of hematologic malignancies—sharing insights that are shaping the future of patient care.
From evolving treatment landscapes to cutting-edge immunotherapies, Moffitt’s contributions will spotlight innovations across the spectrum of blood cancers, including:
Anemia & MDS/MPNs: Latest clinical updates
AML & CPX-351: Emerging treatment strategies
CAR-T in ALL: Integration and toxicity management
High-Risk AML & CML: Novel immune and mutation-based approaches
Case Insights: Practical, patient-focused applications
Our mission is to transform the treatment of blood cancers through research-driven, patient-centered care. At SOHO 2025, Moffitt’s experts will showcase the science, collaboration, and innovation driving that mission forward.
Follow Moffitt to learn more about Moffitt’s research and breakthroughs:
LinkedIn
X | MoffittNews
Email

![]() Dr. Rami Komrokji The Evolving Landscape of Anemia in MDS & MPNs: Clinical Updates and Best Practices |
![]() Dr. Jeffrey Lancet Meet the Professor Session: Future Role of CPX-351 and CPX-351-Based Combinations |
![]() Dr. Rami Komrokji Meet the Professor Session: Promising Studies in MDS in 2025 |
![]() Dr. Javier Pinilla-Ibarz Meet the Professor Session - Case: Why I Started This Patient on VenG |
![]() Dr. Fred Locke Meet the Professor Session: Emerging Toxicities of CAR-T |
![]() Dr. Bijal Shah Level 3, General Assembly Oral: CAR T Cells in ALL: Early Integration in Newly Diagnosed High-Risk ALL and Optimization of Post CAR T-Cells Outcome in Relapsed-Refractory Disease |
![]() Dr. David Sallman Oral - Novel Strategies in High-Risk AML- Focus on Immune-Based Strategies |
![]() Dr. Kendra Sweet Breakfast With The Expert - When Do You Do Mutation Testing in CML and How Do You Decide If It Is Meaningful |